ASX Linkedin Twitter               

 

Scientific Presentations 2013

Presentation Title Conference Date
CALM study: a phase II study of intratumoral Coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma 8th World Congress of Melanoma, Hamburg 17 – 20 July 2013.
Major synergy between Coxsackievirus A21 (CAVATAKTM) and radiotherapy or chemotherapy in bladder cancer cell lines, due to up-regulation viral receptors ICAM-1 & DAF The Seventh International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec, Canada 15-18 June 2013.
Investigation of Potential Oncolytic Effects of Replication-Competent Coxsackievirus A21 (CVA21) in Combination with Chemotherapy on Various Lung Carcinomas The Seventh International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec, Canada 15-18 June 2013.
Combinatory Effects of Docetaxel with the Naturally Occurring Oncolytic Virus Coxsackievirus A21 (CVA21) The Seventh International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec, Canada 15-18 June 2013.
Coxsackievirus A21 (CVA21) Immune Cell Interactions and Oncolytic Activity in Leukaemia The Seventh International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec, Canada 15-18 June 2013.
CALM study A Phase II study of intratumoural Coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma American Society of Clinical Oncology, Chicago 31 May – 4 Jun, 2013.
Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).